S Rangarajan

Summary

Affiliation: Guy's and St Thomas' NHS Foundation Trust
Country: UK

Publications

  1. doi The clinical implications of ADAMTS13 function: the perspectives of haemostaseologists
    Savita Rangarajan
    Centre for Haemostasis and Thrombosis, Guy s and St Thomas NHS Foundation Trust, London Electronic address
    Thromb Res 132:403-7. 2013
  2. doi Consensus recommendations for the use of FEIBA(®) in haemophilia A patients with inhibitors undergoing elective orthopaedic and non-orthopaedic surgery
    S Rangarajan
    Centre for Haemostasis and Thrombosis, St Thomas Hospital, London, UK
    Haemophilia 19:294-303. 2013
  3. doi Will gene therapy trump factor treatment in hemophilia?
    Savita Rangarajan
    Centre for Haemostasis and Thrombosis, Guy s and St Thomas NHS Foundation Trust, St Thomas Hospital, London, UK
    Expert Rev Hematol 6:43-8. 2013
  4. doi Experience of four UK comprehensive care centres using FEIBA® for surgeries in patients with inhibitors
    S Rangarajan
    Centre for Haemostasis and Thrombosis, St Thomas Hospital, London, UK
    Haemophilia 17:28-34. 2011
  5. doi Von Willebrand factor--two sides and the edge of a coin
    S Rangarajan
    Haemostasis and Thrombosis Centre, Basingstoke and North Hampshire Foundation Trust, Basingstoke, UK
    Haemophilia 17:61-4. 2011
  6. doi Pharmacokinetics, coagulation factor consumption and clinical efficacy in patients being switched from full-length FVIII treatment to B-domain-deleted r-FVIII and back to full-length FVIII
    C Rea
    Haemostasis Research Unit, Centre for Haemophilia and Thrombosis, Guy s and St Thomas NHS Foundation Trust, London, UK
    Haemophilia 15:1237-42. 2009
  7. doi Stabilization of fibrin clots by activated prothrombin complex concentrate and tranexamic acid in FVIII inhibitor plasma
    L Dai
    Centre for Haemostasis and Thrombosis, St Thomas Hospital, London, UK
    Haemophilia 17:e944-8. 2011
  8. ncbi A study of the prevalence of vitamin K deficiency in patients with cancer referred to a hospital palliative care team and its association with abnormal haemostasis
    D J Harrington
    Centre for Haemostasis and Thrombosis, Guy s and St Thomas NHS Foundation Trust, London, UK
    J Clin Pathol 61:537-40. 2008
  9. ncbi Further evidence of false negative screening for lupus anticoagulants
    G W Moore
    Centre for Haemostasis and Thrombosis, Haemophilia Reference Centre, 1st Floor North Wing, St Thomas Hospital, Lambeth Palace Road, London SE1 7EH, England
    Thromb Res 121:477-84. 2008
  10. ncbi Low frequency of elevated prothrombin times in patients with lupus anticoagulants when using a recombinant thromboplastin reagent: implications for dosing and monitoring of oral anticoagulant therapy
    G W Moore
    Centre for Haemostasis and Thrombosis The Haemophilia Reference Centre, St Thomas Hospital, London, UK
    Br J Biomed Sci 62:15-8; quiz 47. 2005

Collaborators

Detail Information

Publications14

  1. doi The clinical implications of ADAMTS13 function: the perspectives of haemostaseologists
    Savita Rangarajan
    Centre for Haemostasis and Thrombosis, Guy s and St Thomas NHS Foundation Trust, London Electronic address
    Thromb Res 132:403-7. 2013
    ..This includes stroke, myocardial infarction, sepsis and inflammatory condition. This article reviews the literature in these conditions. ..
  2. doi Consensus recommendations for the use of FEIBA(®) in haemophilia A patients with inhibitors undergoing elective orthopaedic and non-orthopaedic surgery
    S Rangarajan
    Centre for Haemostasis and Thrombosis, St Thomas Hospital, London, UK
    Haemophilia 19:294-303. 2013
    ..The consensus recommendations provide a standardized approach to the dosing and monitoring of FEIBA...
  3. doi Will gene therapy trump factor treatment in hemophilia?
    Savita Rangarajan
    Centre for Haemostasis and Thrombosis, Guy s and St Thomas NHS Foundation Trust, St Thomas Hospital, London, UK
    Expert Rev Hematol 6:43-8. 2013
    ..It is hoped that with the profusion of clinical trial programs in hemophilia care, it will eventually provide affordable treatment to many patients who currently cannot access adequate treatment in the developing countries...
  4. doi Experience of four UK comprehensive care centres using FEIBA® for surgeries in patients with inhibitors
    S Rangarajan
    Centre for Haemostasis and Thrombosis, St Thomas Hospital, London, UK
    Haemophilia 17:28-34. 2011
    ..This case series adds significantly to existing evidence that FEIBA can provide adequate, well-tolerated, peri-operative haemostatic cover for a wide variety of major and minor surgical procedures...
  5. doi Von Willebrand factor--two sides and the edge of a coin
    S Rangarajan
    Haemostasis and Thrombosis Centre, Basingstoke and North Hampshire Foundation Trust, Basingstoke, UK
    Haemophilia 17:61-4. 2011
    ..There is also a debatable function of protecting factor VIII (FVIII) in circulation with the prevention of development of FVIII inhibitors. This commentary addresses these functions...
  6. doi Pharmacokinetics, coagulation factor consumption and clinical efficacy in patients being switched from full-length FVIII treatment to B-domain-deleted r-FVIII and back to full-length FVIII
    C Rea
    Haemostasis Research Unit, Centre for Haemophilia and Thrombosis, Guy s and St Thomas NHS Foundation Trust, London, UK
    Haemophilia 15:1237-42. 2009
    ..BDD rFVIII was found to be equivalent to other FVIII products in terms of pharmacokinetics, clinical efficacy and safety in this study group...
  7. doi Stabilization of fibrin clots by activated prothrombin complex concentrate and tranexamic acid in FVIII inhibitor plasma
    L Dai
    Centre for Haemostasis and Thrombosis, St Thomas Hospital, London, UK
    Haemophilia 17:e944-8. 2011
    ..Our results suggest that the combination of pd-aPCC with TXA improves clot stability in FVIII inhibitor plasma without additional increases in thrombin generation...
  8. ncbi A study of the prevalence of vitamin K deficiency in patients with cancer referred to a hospital palliative care team and its association with abnormal haemostasis
    D J Harrington
    Centre for Haemostasis and Thrombosis, Guy s and St Thomas NHS Foundation Trust, London, UK
    J Clin Pathol 61:537-40. 2008
    ..Many patients with advanced cancer are malnourished. Anorexia is common, as is the use of chemotherapy, which may cause nausea and poor appetite. Ten per cent of these patients experience haemorrhagic events...
  9. ncbi Further evidence of false negative screening for lupus anticoagulants
    G W Moore
    Centre for Haemostasis and Thrombosis, Haemophilia Reference Centre, 1st Floor North Wing, St Thomas Hospital, Lambeth Palace Road, London SE1 7EH, England
    Thromb Res 121:477-84. 2008
    ..Antibody heterogeneity and assay variability complicate LA detection and weak antibodies can go undetected...
  10. ncbi Low frequency of elevated prothrombin times in patients with lupus anticoagulants when using a recombinant thromboplastin reagent: implications for dosing and monitoring of oral anticoagulant therapy
    G W Moore
    Centre for Haemostasis and Thrombosis The Haemophilia Reference Centre, St Thomas Hospital, London, UK
    Br J Biomed Sci 62:15-8; quiz 47. 2005
    ....
  11. doi Molecular characterization of 11 novel mutations in patients with heterozygous and homozygous FV deficiency
    J A Cutler
    Centre for Haemostasis and Thrombosis, St Thomas Hospital, London, UK
    Haemophilia 16:937-42. 2010
    ..The addition of a significant number of previously unidentified mutations to the public domain will contribute to the knowledge and understanding of the molecular pathology of this rare disorder...
  12. doi Three dominant-negative mutations in factor XI-deficient patients
    L Dai
    Haemostasis Research Unit, Centre for Haemostasis and Thrombosis, Guy s and St Thomas NHS Foundation and Kings College London School of Medicine, London, UK
    Haemophilia 17:e919-22. 2011
    ..9%, 68.6% or 71.4%, respectively. Our study suggests that dominant-negative mutations in FXI-deficient patients of non-Ashkenazi Jewish origin may be more prevalent than thought, resulting from FXI's unique dimeric structure...
  13. doi Pharmacokinetic and pharmacodynamic properties of plasma-derived vs. recombinant factor IX in patients with hemophilia B: a prospective crossover study
    J Alamelu
    Centre for Haemostasis and Thrombosis, Guy s and St Thomas NHS Foundation Trust, London, UK
    J Thromb Haemost 12:2044-8. 2014
    ..Lower recovery values have been reported following administration of recombinant FIX (rFIX) than following administration of plasma-derived FIX (pdFIX)...
  14. ncbi Alteration in the laboratory profile of a lupus anticoagulant in a patient with non-Hodgkin's lymphoma
    G W Moore
    Centre for Haemostasis and Thrombosis, Haemophilia Reference Centre, St Thomas Hospital, London, UK
    Clin Lab Haematol 26:429-34. 2004
    ..The changing laboratory profile over time demonstrates the effects of LA heterogeneity and variations in sensitivity and specificity of assays for the detection of antiphospholipid antibodies...